FDA to Host Webinar Celebrating 10th Anniversary of "The Real Cost" Campaign

Regulations by 2FIRSTS.ai
May.10.2024
FDA to Host Webinar Celebrating 10th Anniversary of "The Real Cost" Campaign
FDA to host webinar to celebrate 10th anniversary of "The Real Cost" youth tobacco prevention campaign on June 11.

According to a recent announcement on the official website of the U.S. Food and Drug Administration (FDA), the FDA will be hosting a webinar on June 11th from 3:00 to 4:15 pm EST to commemorate the 10th anniversary of the award-winning "The Real Cost" youth tobacco prevention campaign.

 

The speaker will discuss the impact of tobacco use on adolescents and the importance of public education in regulating tobacco products comprehensively at this conference. They will also emphasize the adaptability of the event, successful case studies, future prospects, as well as media positioning, creative development, and best practices aimed at adolescents.

 

The agenda for this seminar is as follows:

 

The agenda begins at 3:00 pm. Dr. Brian King, Director of the Tobacco Center, will be speaking.

 

3:10 pm seminar keynote address - The Power of Prevention: Building on a Decade of Success in Public Education and Youth Tobacco Prevention

 

Question and answer session at 4:00 pm

 

The online seminar will be free to attend, but registration is required beforehand with no deadline. The seminar can be accessed via computer or mobile phone, and live captions and American Sign Language interpretation will be provided on-site.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Highlights Product Characterization as a Foundational Requirement in ENDS PMTA Reviews
FDA Highlights Product Characterization as a Foundational Requirement in ENDS PMTA Reviews
During its ongoing PMTA roundtable, FDA emphasized that product characterization is a foundational element in the review of electronic nicotine delivery systems (ENDS). The agency underscored the need for complete product identifying information, validation and verification of test methods on the specific product type, and the appropriate use of tobacco product master files (TPMFs) to support complex or proprietary ingredients in PMTA submissions.
Feb.10
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
The U.S. Food and Drug Administration has confirmed that six on! PLUS nicotine pouch products have received Marketing Granted Orders (MGO) through the PMTA pathway. The authorizations were completed under the agency’s nicotine pouch review pilot program in “record time,” with the FDA citing lower levels of harmful constituents while stressing that the decision applies only to the specified products and does not mean they are safe or FDA approved.
Regulations
Dec.20
Japan Tobacco seeks retail price hike for Ploom tobacco sticks; EVO and others to rise by 30 yen per pack
Japan Tobacco seeks retail price hike for Ploom tobacco sticks; EVO and others to rise by 30 yen per pack
Japan Tobacco (JT) said it has applied to raise retail prices for its heated tobacco-related products from April 1, 2026, covering 37 variants of Ploom tobacco sticks and with capsules, with most increases at 20–30 yen per pack (about $0.13–$0.19).
Jan.28 by 2FIRSTS.ai
Vietnam’s Health Ministry consults on tobacco-control law amendments, proposing an e-cigarette ban
Vietnam’s Health Ministry consults on tobacco-control law amendments, proposing an e-cigarette ban
VTV.vn reports that Vietnam’s Ministry of Health is collecting feedback on a draft amendment to the Law on Prevention and Control of Tobacco Harms, proposing an e-cigarette ban and broader public health protections.
Jan.13 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
Philip Morris International said it presented scientific evidence to the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee to support its ZYN nicotine pouches seeking a modified risk tobacco product designation, which would allow the company to communicate to adult smokers that switching completely to ZYN could reduce the risk of multiple smoking-related diseases.
Jan.26 by 2FIRSTS.ai